Sign up Australia
Proactive Investors - Run By Investors For Investors

MaxCyte's Doug Doerfler 'confident of providing long-term treatment' for CGD patients

Doug Doerfler, president and chief executive of MaxCyte, Inc. (LON:MXCT) tells Proactive they're to continue their collaboration with one of the world’s leading infectious disease institutes after signing a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAD).

The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s Flow Electroporation gene-correction platform.

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Article
October 10 2018

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use